Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.

Alfedi G, Luffarelli R, Condò I, Pedini G, Mannucci L, Massaro DS, Benini M, Toschi N, Alaimo G, Panarello L, Pacini L, Fortuni S, Serio D, Malisan F, Testi R, Rufini A.

Mov Disord. 2019 Mar;34(3):323-334. doi: 10.1002/mds.27604. Epub 2019 Jan 9.

PMID:
30624801
2.

E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.

Benini M, Fortuni S, Condò I, Alfedi G, Malisan F, Toschi N, Serio D, Massaro DS, Arcuri G, Testi R, Rufini A.

Cell Rep. 2017 Feb 21;18(8):2007-2017. doi: 10.1016/j.celrep.2017.01.079.

3.

Transcatheter Valve Unable to Cure Patient-Prosthesis Mismatch of Mosaic Bioprosthesis.

Serio D, Zierer A, Doss M, Moritz A.

Thorac Cardiovasc Surg Rep. 2016 Dec;5(1):27-29. doi: 10.1055/s-0036-1583298. Epub 2016 Jun 1.

4.

Reply.

Serio D, Doss M, Walther T.

Ann Thorac Surg. 2017 Jan;103(1):366. doi: 10.1016/j.athoracsur.2016.08.054. No abstract available.

PMID:
28007252
5.

Limited Expansion of the New Self-Expandable Transcathether Aortic Valve Prosthesis (CoreValve Evolut R).

Serio D, Doss M, Kim WK, Möllmann H, Walther T.

Ann Thorac Surg. 2016 May;101(5):e137-8. doi: 10.1016/j.athoracsur.2015.08.089.

PMID:
27106459
6.

Hematological and biochemical findings in pregnant, postfoaling, and lactating jennies.

Bonelli F, Rota A, Corazza M, Serio D, Sgorbini M.

Theriogenology. 2016 Apr 15;85(7):1233-8. doi: 10.1016/j.theriogenology.2015.12.004. Epub 2015 Dec 18.

PMID:
26792379
7.

Src inhibitors modulate frataxin protein levels.

Cherubini F, Serio D, Guccini I, Fortuni S, Arcuri G, Condò I, Rufini A, Moiz S, Camerini S, Crescenzi M, Testi R, Malisan F.

Hum Mol Genet. 2015 Aug 1;24(15):4296-305. doi: 10.1093/hmg/ddv162. Epub 2015 May 6.

PMID:
25948553
8.

Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells.

Rufini A, Cavallo F, Condò I, Fortuni S, De Martino G, Incani O, Di Venere A, Benini M, Massaro DS, Arcuri G, Serio D, Malisan F, Testi R.

Neurobiol Dis. 2015 Mar;75:91-9. doi: 10.1016/j.nbd.2014.12.011. Epub 2014 Dec 27.

9.

Specific personality traits and coping styles predict affective symptoms in early post acute coronary syndrome inpatients.

De Fazio P, Caroleo M, Rizza P, Cerminara G, De Serio D, Indolfi C, Segura-García C.

Int J Psychiatry Med. 2012;44(2):119-32.

PMID:
23413659
10.

Mitogen-activated protein kinases activation in T lymphocytes of patients with acute coronary syndromes.

Indolfi C, Gasparri C, Vicinanza C, De Serio D, Boncompagni D, Mongiardo A, Spaccarotella C, Agosti V, Torella D, Curcio A.

Basic Res Cardiol. 2011 Jun;106(4):667-79. doi: 10.1007/s00395-011-0172-1. Epub 2011 Mar 20.

PMID:
21424618
11.

Frataxin participates to the hypoxia-induced response in tumors.

Guccini I, Serio D, Condò I, Rufini A, Tomassini B, Mangiola A, Maira G, Anile C, Fina D, Pallone F, Mongiardi MP, Levi A, Ventura N, Testi R, Malisan F.

Cell Death Dis. 2011 Feb 24;2:e123. doi: 10.1038/cddis.2011.5.

12.

Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia.

Rufini A, Fortuni S, Arcuri G, Condò I, Serio D, Incani O, Malisan F, Ventura N, Testi R.

Hum Mol Genet. 2011 Apr 1;20(7):1253-61. doi: 10.1093/hmg/ddq566. Epub 2011 Jan 7.

PMID:
21216878
13.

Molecular control of the cytosolic aconitase/IRP1 switch by extramitochondrial frataxin.

Condò I, Malisan F, Guccini I, Serio D, Rufini A, Testi R.

Hum Mol Genet. 2010 Apr 1;19(7):1221-9. doi: 10.1093/hmg/ddp592. Epub 2010 Jan 6.

PMID:
20053667
14.

Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation.

Ispanovic E, Serio D, Haas TL.

Am J Physiol Cell Physiol. 2008 Sep;295(3):C600-10. doi: 10.1152/ajpcell.00460.2007. Epub 2008 Jun 18.

15.

Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, Surace FC, Cavaliere AL, Leone A, Coppola C, Ellison GM, Indolfi C.

Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2935-43. Epub 2007 Feb 9.

16.

Palangeal quantitative ultrasound, phalangeal morphometric variables, and vertebral fracture discrimination.

Guglielmi G, Njeh CF, de Terlizzi F, De Serio DA, Scillitani A, Cammisa M, Fan B, Lu Y, Genant HK.

Calcif Tissue Int. 2003 Apr;72(4):469-77. Epub 2003 Feb 10.

PMID:
12574870
17.

Intravirion display of a peptide corresponding to the dimer structure of protease attenuates HIV-1 replication.

Cartas M, Singh SP, Serio D, Rizvi TA, Kalyanaraman VS, Goldsmith CS, Zaki SR, Weber IT, Srinivasan A.

DNA Cell Biol. 2001 Dec;20(12):797-805.

PMID:
11879573
18.
19.
20.

Suppression of HIV-1 transcription and replication by a Vpr mutant.

Sawaya BE, Khalili K, Rappaport J, Serio D, Chen W, Srinivasan A, Amini S.

Gene Ther. 1999 May;6(5):947-50.

21.

HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication.

Srivastava M, Cartas M, Rizvi TA, Singh SP, Serio D, Kalyanaraman VS, Pollard HB, Srinivasan A.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2704-9.

22.

Epitope-based assay to determine the efficiency of cleavage by HIV-1 protease.

Serio D, Weber IT, Harrison RW, Louis JM, Srinivasan A.

Biotechniques. 1999 Feb;26(2):242-4, 246. No abstract available.

23.

Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.

Serio D, Rizvi TA, Cartas M, Kalyanaraman VS, Weber IT, Koprowski H, Srinivasan A.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3346-51.

Supplemental Content

Support Center